Supernus Pharmaceuticals, Inc.

This study tests whether SPN-817 can reduce seizure frequency in adults with focal onset seizures that don't respond well to current medications. About 216 participants will receive either SPN-817 or a placebo, and researchers will track seizure changes over 14 weeks. The goal is…

This study tests a new drug called SPN-817 in 60 adults whose epilepsy does not improve with standard treatments. The main goal is to see if the drug is safe and tolerable. Researchers will also track whether it reduces the number of motor seizures. Participants take the drug as …

This study tests the long-term safety and effectiveness of a drug called SPN-817 in adults with focal onset seizures (a type of epilepsy). About 100 people who completed a previous SPN-817 study will take the drug for one year. Researchers will track side effects and measure chan…

This study tests whether a new drug called SPN-821 can help adults with major depressive disorder who are already taking an antidepressant. About 230 participants will receive either SPN-821 or a placebo for 29 days. The main goal is to see if the drug reduces depression symptoms…

This study tests whether a medication called SPN-812 (viloxazine) can safely reduce ADHD symptoms in children aged 4 to 5. About 286 kids will receive either the drug or a placebo for 6 weeks. The goal is to see if the drug improves attention and reduces hyperactivity better than…

This study follows 120 people with Parkinson's disease who are using a continuous apomorphine infusion pump (ONAPGO™) to see how it works in real-world settings. Researchers will track how long it takes to find the right dose, any changes to other Parkinson's medications, and how…